Fridtjof Lund-Johansen

• Kared, Hassen; Jyssum, Ingrid; Alirezaylavasani, Amin; Egner, Ingrid Marie; The Tran, Trung & Tietze, Lisa [Show all 17 contributors for this article] (2024). Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study. Frontiers in Immunology. ISSN 1664-3224. 15. doi: 10.3389/fimmu.2024.1296273.
• Gainullin, Murat; Federico, Lorenzo; Osen, Julie Røkke; Chaban, Viktoriia; Kared, Hassen & Alirezaylavasani, Amin [Show all 18 contributors for this article] (2023). People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination. Frontiers in Immunology. ISSN 1664-3224. 14:1235210, p. 1–13. doi: 10.3389/fimmu.2023.1235210. Full text in Research Archive
• Kared, Hassen; Alirezaylavasani, Amin; Lund, Kathrine Persgård; Chopra, Adity; Tietze, Lisa & de Matos Kasahara, Taissa [Show all 17 contributors for this article] (2023). Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients. EBioMedicine. ISSN 2352-3964. 97. doi: 10.1016/j.ebiom.2023.104833. Full text in Research Archive
• Földvári, Zsofia; Knetter, Cathrine; Yang, Weiwen; Gjerdingen, Thea Johanne; Bollineni, Ravi Chand & Tran, Trung [Show all 12 contributors for this article] (2023). A systematic safety pipeline for selection of T-cell receptors to enter clinical use. npj Vaccines. ISSN 2059-0105. 8(1). doi: 10.1038/s41541-023-00713-y.
• Federico, Lorenzo; Tvedt, Tor Henrik Anderson; Gainullin, Murat; Osen, Julie Røkke; Chaban, Viktoriia & Lund, Kathrine Persgård [Show all 19 contributors for this article] (2023). Robust spike-specific CD4⁺ and CD8⁺ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study. Frontiers in Immunology. ISSN 1664-3224. 14. doi: 10.3389/fimmu.2023.1210899. Full text in Research Archive
• Wolf, Asia-Sophia Fumika Michaela; Ravussin, Anthony; König, Marton; Øverås, Mathias Herstad; Solum, Guri & Kjønstad, Ingrid Fadum [Show all 18 contributors for this article] (2023). T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis. JCI Insight. ISSN 2379-3708. 8(12), p. 1–14. doi: 10.1172/jci.insight.165111. Full text in Research Archive
• Nissen-Meyer, Lise Sofie Haug; Steinsvåg, Christine Torsvik; Fenstad, Mona H.; Sørvoll, Ingvild Hausberg; Hvalryg, Marte & Titze, Thomas Larsen [Show all 20 contributors for this article] (2023). Convalescent plasma from Norwegian blood donors to treat COVID-19. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(11), p. 953–957. doi: 10.4045/tidsskr.22.0180. Full text in Research Archive
• Åsberg, Anders; Hovd, Markus Herberg; Kjellevold, Stig Arne; Stenehjem, Aud Eldrid; Wien, Tale Norbye & Broch, Lars Ulrik [Show all 15 contributors for this article] (2023). Humoral Response After 6 or More Successive Doses of SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients-Should We Keep Vaccinating? Transplantation. ISSN 0041-1337. 107(10), p. e279–e280. doi: 10.1097/TP.0000000000004732. Full text in Research Archive
• Amstutz, Alain; Speich, Benjamin; Mentré, France; Rüegg, Corina Silvia; Belhadi, Drifa & Assoumou, Lambert [Show all 35 contributors for this article] (2023). Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Respiratory Medicine. ISSN 2213-2600. 11(5), p. 453–464. doi: 10.1016/S2213-2600(22)00528-8.
• Ravussin, Anthony; Robertson, Anna Hayman; Wolf, Asia-Sophia Fumika Michaela; Blix, Kristine; Kjønstad, Ingrid Fadum & Solum, Guri [Show all 13 contributors for this article] (2023). Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study. The Lancet Healthy Longevity. ISSN 2666-7568. 4(5), p. e188–e199. doi: 10.1016/S2666-7568(23)00055-7. Full text in Research Archive
• Hovd, Markus Herberg; Åsberg, Anders; Munthe, Ludvig Andre; Heldal, Kristian; Reisæter, Anna Varberg & Vaage, John T. [Show all 8 contributors for this article] (2023). Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study. EClinicalMedicine. ISSN 2589-5370. 60. doi: 10.1016/j.eclinm.2023.102035. Full text in Research Archive
• Humbert, Marion; Olofsson, Anna; Wullimann, David; Niessl, Julia; Hodcroft, Emma B. & Cai, Curtis [Show all 20 contributors for this article] (2023). Functional SARS-CoV-2 cross-reactive CD4⁺ T cells established in early childhood decline with age. Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 120(12). doi: 10.1073/pnas.2220320120. Full text in Research Archive
• Selvakumar, Joel Pradeepkumar; Havdal, Lise Beier; Drevvatne, Martin Solstrand; Brodwall, Elias Myrstad; Lund-Berven, Lise & Stiansen-Sonerud, Tonje [Show all 19 contributors for this article] (2023). Prevalence and Characteristics Associated With Post-COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults. JAMA Network Open. ISSN 2574-3805. 6(3). doi: 10.1001/jamanetworkopen.2023.5763. Full text in Research Archive
• Jørgensen, Kristin Kaasen; Høivik, Marte Lie; Chopra, Adity; Saltyte Benth, Jurate; Ricanek, Petr & Moum, Bjørn Allan [Show all 18 contributors for this article] (2023). Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 58(8), p. 874–882. doi: 10.1080/00365521.2023.2177884. Full text in Research Archive
• Meyer, Saskia; Blaas, Isaac; Bollineni, Ravi Chand; Delic-Sarac, Marina; Tran, Trung & Knetter, Cathrine [Show all 20 contributors for this article] (2023). Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. Cell reports. ISSN 2211-1247. 42(1). doi: 10.1016/j.celrep.2023.111995. Full text in Research Archive
• Trøseid, Marius; Arribas, José R.; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien & Terzić, Vida [Show all 56 contributors for this article] (2023). Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID‑19 (Bari‑SolidAct): a randomised, double‑blind, placebo‑controlled phase 3 trial. Critical Care. ISSN 1364-8535. 27, p. 1–15. doi: 10.1186/s13054-022-04205-8. Full text in Research Archive
• Sommen, Silke Lauren; Havdal, Lise Beier; Selvakumar, Joel Pradeepkumar; Einvik, Gunnar; Leegaard, Truls Michael & Lund-Johansen, Fridtjof [Show all 12 contributors for this article] (2022). Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19. Frontiers in Immunology. ISSN 1664-3224. 13, p. 1–12. doi: 10.3389/fimmu.2022.1081718. Full text in Research Archive
• Robert, Philippe Paul Auguste; Akbar, Rahmad; Frank, Robert; Pavlović, Milena; Widrich, Michael & Snapkov, Igor [Show all 25 contributors for this article] (2022). Unconstrained generation of synthetic antibody–antigen structures to guide machine learning methodology for antibody specificity prediction. Nature Computational Science. ISSN 2662-8457. 2(12), p. 845–865. doi: 10.1038/s43588-022-00372-4.
• Tran, Trung; Vaage, Eline Benno; Mehta, Adi; Chopra, Adity; Tietze, Lisa & Kolderup, Heidi Anette [Show all 40 contributors for this article] (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. ISSN 2059-0105. 7(1). doi: 10.1038/s41541-022-00586-7. Full text in Research Archive
• Didriksen, Henriette; Molberg, Øyvind; Mehta, Adi; Jordan, Suzana; Palchevskiy, Vyacheslav & Fretheim, Håvard Halland [Show all 16 contributors for this article] (2022). Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. Frontiers in Immunology. ISSN 1664-3224. 13. doi: 10.3389/fimmu.2022.991743. Full text in Research Archive
• Christensen, Ingrid Egeland; Jyssum, Ingrid; Tveter, Anne Therese; Sexton, Joseph; Tran, Trung & Mjaaland, Siri [Show all 19 contributors for this article] (2022). The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study. BMC Medicine. ISSN 1741-7015. 20(1), p. 1–13. doi: 10.1186/s12916-022-02587-8. Full text in Research Archive Show summary

  Background The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline. Methods IMID patients on immunosuppressive medication enrolled in the prospective observational Nor-vaC study were included. Participants received two-dose SARS-CoV-2 vaccination. Serum collected at two time points following vaccination (first assessment within 6–48 days, second within 49–123 days) were analyzed for antibodies binding the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. Multivariable regression models estimated percent reduction in anti-RBD over 30 days and factors associated with reduction. Results A total of 1108 patients (403 rheumatoid arthritis, 195 psoriatic arthritis, 195 spondyloarthritis, 124 ulcerative colitis, 191 Crohn’s disease) and 134 controls provided blood samples within the defined intervals (median 19 days [IQR 15–24] and 97 days [87–105] after second vaccine dose). Antibody levels were lower in patients compared to controls at both time points, with median anti-RBD 2806 BAU/ml [IQR 1018–6068] in patients and 6187 BAU/ml [4105–7496] in controls (p<0.001) at first assessment, and 608 BAU/ml [IQR 58–1053] in patients and 1520 BAU/ml [979–3766] in controls (p<0.001) at second assessment. At second assessment, low anti-RBD antibody levels (defined as <200 BAU/ml) were found in 449 (41%) patients, and 6 (5%) controls (p<0.001). The change was − 83% in patients and − 66% in controls (p<0.001). Patients had a greater estimated 30 days percent reduction in anti-RBD levels compared to controls − 4.9 (95% CI − 7.4 to − 2.4), (p<0.05). Among therapies, mono- or combination treatment with tumor necrosis factor inhibitors was associated with the greatest decline. Conclusions Within 4 months after vaccination, antibody levels declined considerably in both IMID patients and controls. Patients had lower initial antibody levels and a more pronounced decline compared to healthy controls and were therefore more likely to decline to low antibody levels. These results support that IMID patients need additional vaccine doses at an earlier stage than healthy individuals.

• Granerud, Beathe Kiland; Ueland, Thor; Lind, Andreas; Søraas, Arne Vasli; Fevang, Børre & Steffensen, Anne Katrine [Show all 14 contributors for this article] (2022). Omicron Variant Generates a Higher and More Sustained Viral Load in Nasopharynx and Saliva Than the Delta Variant of SARS-CoV-2. Viruses. ISSN 1999-4915. 14(11). doi: 10.3390/v14112420. Full text in Research Archive Show summary

  The Omicron variant of SARS-CoV-2 spreads more easily than earlier variants, possibly as a result of a higher viral load in the upper respiratory tract and oral cavity. Hence, we investigated whether the Omicron variant generates a higher viral load than that of the Delta variant in saliva and nasopharynx. Both specimens were collected from 52 Omicron and 17 Delta cases at two time points one week apart and analyzed by qRT-PCR. Viral load was measured as 10 log RNA genome copies per 1000 human cells according to the WHO reference standard. We found that Omicron cases carried a higher viral load and had more sustained viral shedding compared to the Delta cases, especially in the nasopharynx.

• Syversen, Silje Watterdal; Jyssum, Ingrid; Tveter, Anne Therese; Tran, Trung; Sexton, Joseph & Provan, Sella Aarrestad [Show all 22 contributors for this article] (2022). Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis & Rheumatology. ISSN 2326-5191. 74(8), p. 1321–1332. doi: 10.1002/art.42153. Full text in Research Archive
• Brunvoll, Sonja Hjellegjerde; Nygaard, Anders Benteson; Ellingjord-Dale, Merete; Holland, Petter; Istre, Mette Stausland & Kalleberg, Karl Trygve [Show all 15 contributors for this article] (2022). Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial. The BMJ. ISSN 1756-1833. 378. doi: 10.1136/bmj-2022-071245. Full text in Research Archive Show summary

  Objective To determine if daily supplementation with cod liver oil, a low dose vitamin D supplement, in winter, prevents SARS-CoV-2 infection, serious covid-19, or other acute respiratory infections in adults in Norway. Design Quadruple blinded, randomised placebo controlled trial. Setting Norway, 10 November 2020 to 2 June 2021. Participants 34601 adults (aged 18-75 years), not taking daily vitamin D supplements. Intervention 5 mL/day of cod liver oil (10 µg of vitamin D, n=17278) or placebo (n=17323) for up to six months. Main outcome measures Four co-primary endpoints were predefined: the first was a positive SARS-CoV-2 test result determined by reverse transcriptase-quantitative polymerase chain reaction and the second was serious covid-19, defined as self-reported dyspnoea, admission to hospital, or death. Other acute respiratory infections were indicated by the third and fourth co-primary endpoints: a negative SARS-CoV-2 test result and self-reported symptoms. Side effects related to the supplementation were self-reported. The fallback method was used to handle multiple comparisons. Results Supplementation with cod liver oil was not associated with a reduced risk of any of the co-primary endpoints. Participants took the supplement (cod liver oil or placebo) for a median of 164 days, and 227 (1.31%) participants in the cod liver oil group and 228 (1.32%) participants in the placebo group had a positive SARS-CoV-2 test result (relative risk 1.00, multiple comparison adjusted confidence interval 0.82 to 1.22). Serious covid-19 was identified in 121 (0.70%) participants in the cod liver oil group and in 101 (0.58%) participants in the placebo group (1.20, 0.87 to 1.65). 8546 (49.46%) and 8565 (49.44%) participants in the cod liver oil and placebo groups, respectively, had ≥1 negative SARS-CoV-2 test results (1.00, 0.97 to 1.04). 3964 (22.94%) and 3834 (22.13%) participants in the cod liver oil and placebo groups, respectively, reported ≥1 acute respiratory infections (1.04, 0.97 to 1.11). Only low grade side effects were reported in the cod liver oil and placebo groups. Co nclusion Supplementation with cod liver oil in the winter did not reduce the incidence of SARS-CoV-2 infection, serious covid-19, or other acute respiratory infections compared with placebo. Trial registration ClinicalTrials.gov NCT04609423.

• Søraas, Arne Vasli; Grødeland, Gunnveig; Granerud, Beathe Kiland; Ueland, Thor; Lind, Andreas & Fevang, Børre [Show all 32 contributors for this article] (2022). Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity. Frontiers in Immunology. ISSN 1664-3224. 13:964525, p. 1–12. doi: 10.3389/fimmu.2022.964525. Full text in Research Archive Show summary

  Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant.

• Ibsen, Jostein Holen; Chopra, Adity; Vaage, Eline Benno; Vaage, John T.; Lund-Johansen, Fridtjof & Lundin, Knut (2022). Immune responses to SARS-CoV-2 vaccines in celiac disease. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 00(0). doi: 10.1080/00365521.2022.2114809. Full text in Research Archive
• Lee, Yunsung; Riskedal, Espen; Kalleberg, Karl Trygve; Istre, Mette Stausland; Lind, Andreas & Lund-Johansen, Fridtjof [Show all 12 contributors for this article] (2022). EWAS of post-COVID-19 patients shows methylation differences in the immune-response associated gene, IFI44L, three months after COVID-19 infection. Scientific Reports. ISSN 2045-2322. 12(1). doi: 10.1038/s41598-022-15467-1. Full text in Research Archive
• Tunheim, Gro; Rø, Gunnar Øyvind Isaksson; Chopra, Adity; Aase, Audun; Kran, Anne-Marte Bakken & Vaage, John T. [Show all 8 contributors for this article] (2022). Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021. Influenza and Other Respiratory Viruses. ISSN 1750-2640. 16(6), p. 1004–1013. doi: 10.1111/irv.13024. Full text in Research Archive
• Kared, Hassen; Wolf, Asia-Sophia Fumika Michaela; Alirezaylavasani, Amin; Ravussin, Anthony; Solum, Guri & Tran, Trung [Show all 17 contributors for this article] (2022). Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nature Communications. ISSN 2041-1723. 13. doi: 10.1038/s41467-022-31888-y. Full text in Research Archive
• Akbar, Rahmad; Bashour, Habib; Rawat, Puneet; Robert, Philippe Paul Auguste; Smorodina, Eva & Cotet, Tudor-Stefan [Show all 15 contributors for this article] (2022). Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. mAbs. ISSN 1942-0862. 14:e2008790(1), p. 1–35. doi: 10.1080/19420862.2021.2008790. Full text in Research Archive
• Anda, Erik Eik; Braaten, Tonje Bjørndal; Borch, Kristin Benjaminsen; Nøst, Therese Haugdahl; Chen, Sairah Lai Fa & Lukic, Marko [Show all 14 contributors for this article] (2022). Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21. Eurosurveillance. ISSN 1025-496X. 27(13), p. 1–10. doi: 10.2807/1560-7917.ES.2022.27.13.2100376. Full text in Research Archive
• Bollineni, Ravi Chand; Tran, Trung; Lund-Johansen, Fridtjof & Olweus, Johanna (2022). Chasing neoantigens; invite naïve T cells to the party. Current Opinion in Immunology. ISSN 0952-7915. 75, p. 1–7. doi: 10.1016/j.coi.2022.102172.
• Akbar, Rahmad; Robert, Philippe Paul Auguste; Weber, Cédric R.; Widrich, Michael; Frank, Robert & Pavlovic, Milena [Show all 19 contributors for this article] (2022). In silico proof of principle of machine learning-based antibody design at unconstrained scale. mAbs. ISSN 1942-0862. 14:e2031482(1), p. 1–18. doi: 10.1080/19420862.2022.2031482. Full text in Research Archive
• König, Marton; Torgauten, Hilde Marie; Tran, Trung; Holmøy, Trygve; Vaage, John T. & Lund-Johansen, Fridtjof [Show all 7 contributors for this article] (2022). Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients with Multiple Sclerosis and Weak Immune Response after COVID-19 Vaccination. JAMA Neurology. ISSN 2168-6149. 79(3), p. 307–309. doi: 10.1001/jamaneurol.2021.5109.
• Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung & Delic-Sarac, Marina [Show all 22 contributors for this article] (2022). Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology. ISSN 0007-1048. 197(6), p. 697–708. doi: 10.1111/bjh.18149. Full text in Research Archive Show summary

  B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.

• Lund-Johansen, Fridtjof; Tran, Trung & Mehta, Adi (2021). Towards reproducibility in large-scale analysis of protein–protein interactions. Nature Methods. ISSN 1548-7091. 18(7), p. 720–721. doi: 10.1038/s41592-021-01202-7.
• Martinez-Val, Ana; Bekker-Jensen, Dorte B.; Steigerwald, Sophia; Koenig, Claire; Østergaard, Ole & Mehta, Adi [Show all 18 contributors for this article] (2021). Spatial-proteomics reveals phospho-signaling dynamics at subcellular resolution. Nature Communications. ISSN 2041-1723. 12(1), p. 1–17. doi: 10.1038/s41467-021-27398-y.
• Jyssum, Ingrid; Kared, Hassen; Tran, Trung; Tveter, Anne Therese; Provan, Sella Aarrestad & Sexton, Joseph [Show all 22 contributors for this article] (2021). Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. The Lancet Rheumatology. doi: 10.1016/S2665-9913(21)00394-5. Full text in Research Archive
• Kåsine, Trine; Riise, Anne Margarita Dyrhol; Barratt-Due, Andreas; Kildal, Anders Benjamin; Olsen, Inge Christoffer & Nezvalova-Henriksen, Katerina [Show all 39 contributors for this article] (2021). Neutrophil count predicts outcome in hospitalized COVID-19 patients. Results from the NOR-Solidarity trial. Journal of Internal Medicine. ISSN 0954-6820. 291(2), p. 241–243. doi: 10.1111/joim.13377. Show summary

  Despite numerous studies on SARS-CoV-2-induced inflammation, we still lack markers for rapid disease progression with admission to intensive care unit (ICU) or respiratory failure(RF). Few studies have evaluated the prognostic value of routine diagnostic repertoire available at most hospitals. The NOR-Solidarity trial is an independent add-on study to the WHO Solidarity trial, evaluating hydroxychloroquine (HCQ)and remdesivir compared to standard of care in hospitalized COVID-19 patients [1]. We explored whether standard biomarkers in peripheral blood could give information on ICU admission and RFin hospitalized COVID-19 patients.

• Helsingen, Lise Mørkved; Løberg, Magnus; Refsum, Erle; Gjøstein, Dagrun Kyte; Wieszczy, Paulina & Olsvik, Ørjan [Show all 16 contributors for this article] (2021). Covid-19 transmission in fitness centers in Norway - a randomized trial. BMC Public Health. ISSN 1471-2458. 21, p. 1–9. doi: 10.1186/s12889-021-12073-0. Full text in Research Archive
• Lerum, Tøri Vigeland; Maltzahn, Niklas; Aukrust, Pål; Trøseid, Marius; Nezvalova-Henriksen, Katerina & Kåsine, Trine [Show all 27 contributors for this article] (2021). Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Scientific Reports. ISSN 2045-2322. 11, p. 1–12. doi: 10.1038/s41598-021-02547-x. Full text in Research Archive Show summary

  The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome.

• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, Trung; Schikora-Rustad, Stine & Vaage, Eline Benno [Show all 22 contributors for this article] (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. ISSN 0022-3050. doi: 10.1136/jnnp-2021-327612. Full text in Research Archive
• Tunheim, Gro; Rø, Gunnar Øyvind Isaksson; Tran, Trung; Kran, Anne-Marte Bakken; Andersen, Jan Terje & Vaage, Eline Benno [Show all 10 contributors for this article] (2021). Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic. Influenza and Other Respiratory Viruses. ISSN 1750-2640. 16(2), p. 204–212. doi: 10.1111/irv.12932. Full text in Research Archive
• Akbar, Rahmad; Robert, Philippe Paul Auguste; Pavlović, Milena; Jeliazkov, Jeliazko R.; Snapkov, Igor & Slabodkin, Andrei [Show all 15 contributors for this article] (2021). A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding. Cell reports. ISSN 2211-1247. 34:108856(11), p. 1–21. doi: 10.1016/j.celrep.2021.108856. Full text in Research Archive
• Barratt-Due, Andreas; Olsen, Inge Christoffer; Nezvalova-Henriksen, Katerina; Kåsine, Trine; Lund-Johansen, Fridtjof & Hoel, Hedda Benedicte [Show all 43 contributors for this article] (2021). Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial. Annals of Internal Medicine. ISSN 0003-4819. 174(9), p. 1261–1269. doi: 10.7326/M21-0653. Full text in Research Archive Show summary

  Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known. Objective: To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx. Design: NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials.gov: NCT04321616). Setting: 23 hospitals in Norway. Patients: Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infection. Intervention: Between 28 March and 4 October 2020, a total of 185 patients were randomly assigned and 181 were included in the full analysis set. Patients received remdesivir (n = 42), HCQ (n = 52), or standard of care (SoC) (n = 87). Measurements: In addition to the primary end point of WHO Solidarity, study-specific outcomes were viral clearance in oropharyngeal specimens, the degree of respiratory failure, and inflammatory variables. Results: No significant differences were seen between treatment groups in mortality during hospitalization. There was a marked decrease in SARS-CoV-2 load in the oropharynx during the first week overall, with similar decreases and 10-day viral loads among the remdesivir, HCQ, and SoC groups. Remdesivir and HCQ did not affect the degree of respiratory failure or inflammatory variables in plasma or serum. The lack of antiviral effect was not associated with symptom duration, level of viral load, degree of inflammation, or presence of antibodies against SARS-CoV-2 at hospital admittance. Limitation: The trial had no placebo group. Conclusion: Neither remdesivir nor HCQ affected viral clearance in hospitalized patients with COVID-19.

• Schultz, Nina Haagenrud; Sørvoll, Ingvild Hausberg; Michelsen, Annika; Munthe, Ludvig Andre; Lund-Johansen, Fridtjof & Ahlen, Maria Therese [Show all 11 contributors for this article] (2021). Thrombosis and thrombocytopenia after CHADOX1 NCoV-19 vaccination. New England Journal of Medicine. ISSN 0028-4793. 384(22), p. 2124–2130. doi: 10.1056/NEJMoa2104882. Full text in Research Archive
• Voskuil, Jan L.A.; Bandrowski, Anita; Begley, C. Glenn; Bradbury, Andrew R.M.; Chalmers, Andrew D. & Gomes, Aldrin V. [Show all 15 contributors for this article] (2020). The Antibody Society’s antibody validation webinar series. mAbs. ISSN 1942-0862. 12:e1794421(1), p. 1–10. doi: 10.1080/19420862.2020.1794421.
• Holter, Jan Cato; Pischke, Soeren; de Boer, Eline; Lind, Andreas; Jenum, Synne & Holten, Aleksander Rygh [Show all 32 contributors for this article] (2020). Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients . Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 117(40), p. 25018–25025. doi: 10.1073/pnas.2010540117. Full text in Research Archive
• de la Rosa-Carrillo, Daniel; Sikorski, Krzysztof; Khnykin, Denis; Wu, Weiwei & Lund-Johansen, Fridtjof (2018). High-resolution antibody array analysis of proteins from primary human keratinocytes and leukocytes. PLOS ONE. ISSN 1932-6203. 13: e0209271(12). doi: 10.1371/journal.pone.0209271. Full text in Research Archive
• Sikorski, Krzysztof; Mehta, Adi; Inngjerdingen, Marit; Thakor, Flourina Kumar; Kling, Simon & Kalina, Tomas [Show all 14 contributors for this article] (2018). A high-throughput pipeline for validation of antibodies. Nature Methods. ISSN 1548-7091. 15(11), p. 909–912. doi: 10.1038/s41592-018-0179-8. Full text in Research Archive Show summary

  Western blotting (WB) is widely used to test antibody specificity, but the assay has low throughput and precision. Here we used preparative gel electrophoresis to develop a capture format for WB. Fractions with soluble, size-separated proteins facilitated parallel readout with antibody arrays, shotgun mass spectrometry (MS) and immunoprecipitation followed by MS (IP-MS). This pipeline provided the means for large-scale implementation of antibody validation concepts proposed by an international working group on antibody validation (IWGAV).Western blotting (WB) is widely used to test antibody specificity, but the assay has low throughput and precision. Here we used preparative gel electrophoresis to develop a capture format for WB. Fractions with soluble, size-separated proteins facilitated parallel readout with antibody arrays, shotgun mass spectrometry (MS) and immunoprecipitation followed by MS (IP-MS). This pipeline provided the means for large-scale implementation of antibody validation concepts proposed by an international working group on antibody validation (IWGAV).

• Vesterhus, Mette; Holm, Anders; Hov, Johannes Espolin Roksund; Nygård, Ståle; Schrumpf, Erik & Melum, Espen [Show all 23 contributors for this article] (2017). Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of Hepatology. ISSN 0168-8278. 66(6), p. 1214–1222. doi: 10.1016/j.jhep.2017.01.019.
• Kanderova, Veronika; Kuzilkova, Daniela; Stuchly, Jan; Vaskova, Martina; Brdicka, Tomas & Fišer, Karel [Show all 9 contributors for this article] (2016). High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Molecular & Cellular Proteomics. ISSN 1535-9476. doi: 10.1074/mcp.M115.054593.
• Pauthner, Matthias; Yeung, Jenny; Ullman, Chris; Bakker, Joost; Wurch, Thierry & Reichert, Janice M. [Show all 10 contributors for this article] (2016). Antibody engineering &amp; therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA. mAbs. ISSN 1942-0862. 8(3), p. 617–652. doi: 10.1080/19420862.2016.1153211.
• Lund-Johansen, Fridtjof; de la Rosa-Carrillo, Daniel; Mehta, Adi; Sikorski, Krzysztof; Inngjerdingen, Marit & Kalina, Tomáš [Show all 11 contributors for this article] (2016). MetaMass, a tool for meta-analysis of subcellular proteomics data. Nature Methods. ISSN 1548-7091. 13(10), p. 837–840. doi: 10.1038/nmeth.3967.
• Strønen, Erlend; Toebes, Mireille; Kelderman, Sander; van Buuren, Marit M.; Yang, Weiwen & Van Rooij, Nienke [Show all 11 contributors for this article] (2016). Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. ISSN 0036-8075. 352(6291), p. 1337–1341. doi: 10.1126/science.aaf2288.
• Vesterhus, Mette; Hov, Johannes Espolin Roksund; Holm, Anders; Schrumpf, Erik; Nygård, Ståle & Godang, Kristin [Show all 25 contributors for this article] (2015). Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. ISSN 0270-9139. 62(1), p. 188–197. doi: 10.1002/hep.27825.
• Ferrara, Fortunato; D'Angelo, Sara; Gaiotto, Tiziano; Naranjo, Leslie; Tian, Hongzhao & Gräslund, Susanne [Show all 13 contributors for this article] (2015). Recombinant renewable polyclonal antibodies. mAbs. ISSN 1942-0862. 7(1), p. 32–41. doi: 10.4161/19420862.2015.989047. Show summary

  Only a small fraction of the antibodies in a traditional polyclonal antibody mixture recognize the target of interest, frequently resulting in undesirable polyreactivity. Here, we show that high-quality recombinant polyclonals, in which hundreds of different antibodies are all directed toward a target of interest, can be easily generated in vitro by combining phage and yeast display. We show that, unlike traditional polyclonals, which are limited resources, recombinant polyclonal antibodies can be ampli fied over one hundred million-fold without losing representation or functionality. Our protocol was tested on 9 different targets to demonstrate how the strategy allows the selective ampli fi cation of antibodies directed toward desirable target speci fi c epitopes, such as those found in one protein but not a closely related one, and the elimination of antibodies recognizing common epitopes, without signi fi cant loss of diversity. These recombinant renewable polyclonal antibodies are usable in different assays, and can be generated in high throughput. This approach could potentially be used to develop highly specific recombinant renewable antibodies against all human gene products.

• Almagro, Juan Carlos; Gilliland, Gary L.; Breden, Felix; Scott, Jamie K.; Sok, Devin & Pauthner, Matthias [Show all 24 contributors for this article] (2014). Antibody engineering & therapeutics, the annual meeting of The Antibody Society. mAbs. ISSN 1942-0862. 6(3), p. 577–618. doi: 10.4161/mabs.28421.
• Kumari, Shraddha; Waelchli, Sebastien; Fallang, Lars-Egil; Yang, Weiwen; Lund-Johansen, Fridtjof & Schumacher, Ton N. [Show all 7 contributors for this article] (2014). Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 111(1), p. 403–408. doi: 10.1073/pnas.1306549111.
• Holm, Anders; Wu, Weiwei & Lund-Johansen, Fridtjof (2012). Antibody array analysis of labelled proteomes: how should we control specificity? New Biotechnology. ISSN 1871-6784. 29(5), p. 578–585. doi: 10.1016/j.nbt.2011.07.008.
• Stuchly, Jan; Kanderova, Veronika; Fišer, Karel; Černá, Daniela; Holm, Anders & Wu, Weiwei [Show all 9 contributors for this article] (2012). An automated analysis of highly complex flow cytometry-based proteomic data. Cytometry. ISSN 0196-4763. 81A(2), p. 120–129. doi: 10.1002/cyto.a.22011.
• Slåstad, Heidi Synnøve; Wu, Weiwei; Goulart, Luiz Fernando De Souza; Kanderova, Veronika; Tjønnfjord, Geir Erland & Stuchly, Jan [Show all 9 contributors for this article] (2011). Multiplexed immuno-precipitation with 1725 commercially available antibodies to cellular proteins. Proteomics. ISSN 1615-9853. 11(23), p. 4578–4582. doi: 10.1002/pmic.201000744. Show summary

  Antibody array analysis of complex samples requires capture reagents with exceptional specificity. The frequency of antibodies with label-based detection may be as low as 5%. Here, however, we show that as many as 25% of commercially available antibodies are useful when biotinylated cellular proteins are fractionated by size exclusion chromatography (SEC) first. A microsphere multiplex with 1725 antibodies to cellular proteins was added to 24 SEC fractions, labelled with streptavidin and analyzed by flow cytometry (microsphere-based affinity proteomics, MAP) The SEC-MAP approach resolved different targets captured by each antibody as reactivity peaks across the separation range of the SEC column (10–670kDa). Complex reactivity profiles demonstrated that most antibodies bound more than one target. However, specific binding was readily detected as reactivity peaks common for different antibodies to the same protein. We optimized sample preparation and found that amine-reactive biotin rarely inhibited antibody binding when the biotin to lysine ratio was kept below 1:1 during labelling. Moreover, several epitopes that were inaccessible to antibodies in native proteins were unmasked after heat denaturation with 0.1% of SDS. The SEC-MAP format should allow researchers to build multiplexed assays with antibodies purchased for use in e.g. Western blotting.

• Abrahamsen, Ingerid Weum; Strønen, Erlend; Waelchli, Sebastien; Johansen, Jorunn; Kumari, Shraddha & Komada, M [Show all 13 contributors for this article] (2010). Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia. ISSN 0887-6924. 24(11), p. 1901–1909. doi: 10.1038/leu.2010.186.
• Di Niro, Roberto; Mesin, Luka; Raki, Melinda; Zheng, Nai-Ying; Lund-Johansen, Fridtjof & Lundin, Knut E A [Show all 10 contributors for this article] (2010). Rapid Generation of Rotavirus-Specific Human Monoclonal Antibodies from Small-Intestinal Mucosa. Journal of Immunology. ISSN 0022-1767. 185(9), p. 5377–5383. doi: 10.4049/jimmunol.1001587.
• Wu, Weiwei; Slåstad, Heidi Synnøve; de la Rosa-Carrillo, Daniel; Frey, T; Tjønnfjord, Geir Erland & Boretti, Eva [Show all 9 contributors for this article] (2009). Antibody Array Analysis with Label-based Detection and Resolution of Protein Size. Molecular & Cellular Proteomics. ISSN 1535-9476. 8(2), p. 245–257. doi: 10.1074/mcp.M800171-MCP200.
• Strønen, Erlend; Abrahamsen, Ingerid Weum; Gaudernack, Gustav; Waelchli, Sebastien; Munthe, Else & Buus, S [Show all 9 contributors for this article] (2009). Dendritic Cells Engineered to Express Defined Allo-HLA Peptide Complexes Induce Antigen-specific Cytotoxic T Cells Efficiently Killing Tumour Cells. Scandinavian Journal of Immunology. ISSN 0300-9475. 69(4), p. 319–328. doi: 10.1111/j.1365-3083.2008.02223.x.
• Wu, Weiwei; Slåstad, Heidi; de la Rosa-Carrillo, Daniel; frey, tom; Tjønnfjord, Geir & Boretti, Eva [Show all 9 contributors for this article] (2008). Antibody array analysis with label-based detection and resolution of protein size. Molecular & Cellular Proteomics. ISSN 1535-9476. doi: 10.1074/mcp.M800171-MCP200.
• Kvale, Espen Østhagen; Fløisand, Yngvar; Lund-Johansen, Fridtjof; Rollag, Halvor; Farkas, Lorant & Ghanekar, Smita [Show all 9 contributors for this article] (2007). Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells. Blood. ISSN 0006-4971. 109. doi: 10.1182/blood-2006-06-031484.
• Villa, Iris Kristine; Kvale, Espen Østhagen; Lund-Johansen, Fridtjof & Olweus, Johanna (2007). Assay for monitoring in vitro selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. ISSN 1465-3249. 9, p. 600–610. doi: 10.1080/14653240701510573.
• Farkas, Lorant; Kvale, Espen Østhagen; Lund-Johansen, Fridtjof & Jahnsen, Frode Lars (2006). Plasmacytoid dendritic cells induce a distinct cytokine pattern in virus-specific CD4(+) memory T cells that is modulated by CpG oligodeoxynucleotides. Scandinavian Journal of Immunology. ISSN 0300-9475. 64, p. 404–411.
• Kvale, Espen Østhagen; Dalgaard, Jakob; Lund-Johansen, Fridtjof; Rollag, Halvor; Farkas, Lorant & Midtvedt, Karsten [Show all 9 contributors for this article] (2006). CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell–stimulatory capability upon infection. Blood. ISSN 0006-4971. 107(5), p. 2022–2029. doi: 10.1182/blood-2005-05-2016.
• Sioud, Mouldy; Fløisand, Yngvar; Forfang, Lise & Lund-Johansen, Fridtjof (2006). Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+progenitor cells along the myeloid lineage. Journal of Molecular Biology (JMB). ISSN 0022-2836. 364(5), p. 945–954. doi: 10.1016/j.jmb.2006.09.054.

View all works in Cristin

• Lund-Johansen, Fridtjof (2023). Antibody Specificity: A strong case for third-party testing. eLIFE. ISSN 2050-084X. 12. doi: 10.7554/eLife.93329.
• Nissen-Meyer, Lise Sofie Haug; Macpherson, Magnhild Eide; Skeie, Linda Gail; Hvalryg, Marte; LLOHN, ABID HUSSAIN & Steinsvåg, Tine Torsvik [Show all 17 contributors for this article] (2023). Covid-19-pasienter behandlet med rekonvalesensplasma. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(11). doi: 10.4045/tidsskr.22.0577. Full text in Research Archive
• Tran, Trung; Vaage, Eline Benno; Mehta, Adi; Chopra, Adity; Tietze, Lisa & Kolderup, Heidi Anette [Show all 40 contributors for this article] (2023). Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants (npj Vaccines, (2022), 7, 1, (174), 10.1038/s41541-022-00586-7). npj Vaccines. ISSN 2059-0105. 8(1). doi: 10.1038/s41541-023-00600-6.
• Rasmussen, Tilde; König, Marton; Lorentzen, Åslaug Rudjord; Schikora-Rustad, Stine; Berge, Tone & Holmøy, Trygve [Show all 17 contributors for this article] (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis.
• König, Marton; Wolf, Asia-Sophia Fumika Michaela; Ravussin, Anthony; Chopra, Adity; Tran, Trung & Torgauten, Hilde Marie [Show all 28 contributors for this article] (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis.
• Midtvedt, Karsten; Vaage, John T.; Heldal, Kristian; Munthe, Ludvig Andre; Lund-Johansen, Fridtjof & Åsberg, Anders (2022). Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. American Journal of Transplantation. ISSN 1600-6135. doi: 10.1111/ajt.17091.
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, The Trung; Schikora-Rustad, Stine & Vaage, Eline Benno [Show all 22 contributors for this article] (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies.
• Midtvedt, Karsten; Tran, Trung; Parker, Krystina; Marti, Hans Peter; Stenehjem, Aud Eldrid & Gøransson, Lasse Gunnar [Show all 12 contributors for this article] (2021). Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up! Transplantation. ISSN 0041-1337. 105(8), p. E80–E81. doi: 10.1097/TP.0000000000003856. Full text in Research Archive
• Olweus, Johanna & Lund-Johansen, Fridtjof (2019). Finding Neo (antigens, that is). Blood. ISSN 0006-4971. 134(2), p. 108–109. doi: 10.1182/blood.2019001334.
• Lund-Johansen, Fridtjof & Browning, Michael D. (2017). Should we ignore western blots when selecting antibodies for other applications? Nature Methods. ISSN 1548-7091. 14(3), p. 215–215. doi: 10.1038/nmeth.4192.
• Freedman, Leonard P.; Gibson, Mark C.; Bradbury, Andrew R.M.; Buchberg, Arthur M.; Davis, Darryl & Dolled-Filhart, Marisa P. [Show all 8 contributors for this article] (2016). The need for improved education and training in research antibody usage and validation practices. BioTechniques. ISSN 0736-6205. 61(1), p. 16–18. doi: 10.2144/000114431.
• Vaskova, Martina; Mejstrikova, Ester; Brdicka, Tomas; Angelisová, P.; Kalina, Tomas & Kanderova, Veronika [Show all 12 contributors for this article] (2011). New Targets in Cytometric Investigation of Acute Leukemia Selected From Gene Profiling Studies. Blood. ISSN 0006-4971. 118(21), p. 1087–1088.
• Carrillo, Daniel de la Rosa; Khnykin, Denis; Holm, Anders; Wu, Weiwei & Lund-Johansen, Fridtjof (2011). Large-scale protein analysis of primary human skin keratinocytes from skin punch biopsies by microsphere-based affinity proteomics. Journal of Investigative Dermatology. ISSN 0022-202X. 131, p. S74–S74.
• Fuentes, Manuel; Bartolome, Raquel; Gonzalez-Gonzalez, Maria; Lund-Johansen, Fridtjof & Orfao, Alberto (2010). FUNCTIONAL PROTEOMICS: BEADS-BASED ARRAY SYSTEM FOR BIOMARKER DISCOVERY. Cytometry. ISSN 0196-4763. 78B(6), p. 453–453.
• Kvale, Espen Østhagen; Fløisand, Yngvar; Lund-Johansen, Fridtjof; Rollag, Halvor; Brandtzæg, Per & Jahnsen, Frode Lars [Show all 7 contributors for this article] (2006). Plasmacytoid dendritic cells regulate recall responses by rapid induction of IL-10 in CD4+ memory T cells. Tissue Antigens. ISSN 0001-2815. 67, p. 443–444.
• Tunheim, Gro; Kran, Anne-Marte Bakken; Rø, Gunnar Øyvind Isaksson; Hungnes, Olav; Lund-Johansen, Fridtjof & Vaage, Eline Benno [Show all 9 contributors for this article] (2021). Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in January 2021 . Norwegian Institute of Public Health, Division of Infection Control and Environmental Health. ISSN 978-82-8406-182-5. Full text in Research Archive
• Tunheim, Gro; Kran, Anne-Marte Bakken; Rø, Gunnar Øyvind Isaksson; Hungnes, Olav; Lund-Johansen, Fridtjof & Tran, Trung [Show all 8 contributors for this article] (2020). Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in late summer 2020. Folkehelseinstituttet. ISSN 978-82-8406-155-9. Show summary

  COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2. Infection with SARS-CoV-2 induces antibodies to the virus, therefore the presence of these antibodies in a person’s blood indicates that the person has been infected with SARS-CoV-2. This is the second study measuring antibodies against SARS-CoV-2 in residual serum samples collected systematically from various geographical regions in Norway and covering all age groups. The first study with residual sera from April/May 2020 and August 2019, was published as a report in June 2020 (1). In the present study, a total of 1812 residual sera were sampled from 16 microbiology laboratories from late July to mid-September 2020 (week numbers 30-37). The sera were tested for antibodies against SARS-CoV-2 using a novel in-house assay established at the Department of Immunology, Oslo University Hospital. Based on these measurements, the estimated seroprevalence in the Norwegian population in the late summer was 0.6% [95% credible interval (CrI) 0.2 - 1.2]. This is not significantly different from the seroprevalence estimate based on the 900 samples collected in the spring (1.0% [95% CrI 0.1- 2.4])(1). Antibodies against SARS-CoV-2 were found in samples from 6 of the 11 counties, but there were no significant differences between the seroprevalence estimates for each county. However, the sample size from each county varied considerably (from 20 to 387) and the number of positive samples were limited (11 in total). There were no significant differences between the seroprevalence estimates for the various age groups or between males and females. During the summer of 2020, the pandemic was quite contained in Norway. This may explain why the estimated seroprevalence for the Norwegian population was similar in the spring and in the late summer. In this first follow-up study, more laboratories contributed, and a greater number of samples was tested, leading to better precision of the seroprevalence estimate. New follow-up studies of antibodies against SARS-CoV-2 in future collections of residual sera will provide further information about the development of the COVID-19 pandemic in Norway

• Tunheim, Gro; Kran, Anne-Marte Bakken; Rø, Gunnar Øyvind Isaksson; Steens, Anneke; Hungnes, Olav & Lund-Johansen, Fridtjof [Show all 9 contributors for this article] (2020). Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in April/May 2020 and August 2019. Folkehelseinstituttet. ISSN 978-82-8406-109-2. Show summary

  COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2. Infection with SARS-CoV-2 induces antibodies to the virus, therefore the presence of these antibodies in a person’s blood indicates that the person has been infected with SARS-CoV-2. This is the first study measuring antibodies against SARS-CoV-2 in serum samples collected systematically from various geographical regions in Norway and covering all age groups. A total of 900 residual sera from nine laboratories were sampled in week numbers 17-20, 2020, and tested for antibodies against SARS-CoV-2 using a novel in-house assay established at the Department of Immunology, Oslo University Hospital. Based on these measurements, the estimated seroprevalence in the Norwegian population is probably close to 1% (1.0% (95% credible interval 0.1% - 2.4%)). We did not find any differences in seroprevalence by gender or age group. However, there seem to be geographical differences in the prevalence of seropositive individuals; there was a non-significant trend indicating that the number of positive samples and the estimated seroprevalence was higher in Oslo than in other regions. However, the sample size was limited as not all counties were included, and only an average number of 100 samples have been collected from each laboratory. Therefore, these results should be interpreted with caution. Follow-up studies of antibodies against SARS-CoV-2 in future collections of residual sera can provide further information about the development of the COVID-19 pandemic in Norway.

• Strand, Martin Frank; Lea, Tor Erling & Lund-Johansen, Fridtjof (2005). Establishment of a test system for multiparameter analysis of intracellular signal pathways by the use of flow cytometry. Universitetet i Oslo.

View all works in Cristin